|This Slide: #100 of 100|
Slide #100. Novartis — CoStim Pharmaceuticals, Inc.
CoStim Pharmaceuticals, Inc.
MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. ("CoStim") has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.
Novartis is a multinational group focusing on the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals and also including generic pharmaceuticals and eye care products. Co. comprises three global operating divisions: Innovative Medicines Division, which researches, develops, manufactures, distributes and sells patented prescription medicines; Sandoz Division, which develops, manufactures, distributes and sells prescription medicines as well as pharmaceutical active substances; and Alcon Division, which researches, develops, manufactures, distributes and sells eye care products.
Open the NVS Page at The Online Investor »
Buy (3.33 out of 4)
(ranked higher than approx. 53% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite